Shrinkage of pituitary adenomas with pasireotide - Authors' reply

Lancet Diabetes Endocrinol. 2019 Jul;7(7):509-510. doi: 10.1016/S2213-8587(19)30186-X.

Authors

Eva C Coopmans¹, Aart J van der Lely², Joppe J Schneiders³, Sebastian J C M M Neggers²

Affiliations

¹ Pituitary Center Rotterdam, Endocrinology Section, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, 3015 GD, Netherlands. Electronic address: e.coopmans@erasmusmc.nl.
² Pituitary Center Rotterdam, Endocrinology Section, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, 3015 GD, Netherlands.
³ Department of Radiology, Erasmus University Medical Center, Rotterdam, 3015 GD, Netherlands.

PMID: 31227248
DOI: 10.1016/S2213-8587(19)30186-X

No abstract available

Publication types

Letter
Comment

MeSH terms

Acromegaly*
Adenoma*
Humans
Pituitary Neoplasms*
Somatostatin / analogs & derivatives

Substances

Somatostatin
pasireotide